Bio

Since 2000, Kolon Life Science has been developing innovative cell and gene therapeutics.
Currently, Kolon Life Science has 5 projects in its development pipeline including the world’s first cell mediated gene therapy for Osteoarthritis.

With the experience and expertise in the cell and gene therapeutic areas, Kolon Life Science will continue to thrive as a successful new drug development company and become a trusted partner through its global R&D network.

Through challenging development and successful commercialization in INVOSSA and other new drugs, Kolon Life Science will continue to grow as a global leading bio-company, contributing to improving the quality of life for patients worldwide.

KOLON LIFE SCIENCE, DEVELOPING A NOVEL THERAPY FOR OSTEOARTHRITIS SINCE 2000. To improve the quality of life for patients worldwide